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CHANGES IN PRESCRIPTIONS DISPENSED ON PROTON PUMP 
INHIBITORS (PPIS) FOLLOWING NEW RESTRICTIONS FOR 
REIMBURSEMENT – A NATIONWIDE NORWEGIAN PRESCRIPTION
DATABASE STUDY
Jonasson C1, Tvete I2, Jørgensen E1, Hatlebakk JG3
1AstraZeneca AS, Oslo, Norway, 2Norwegian Computing Centre, Oslo, Norway, 3University 
of Bergen, Bergen, Norway
OBJECTIVES: To assess the changes in PPI prescriptions dispensed after the introduc-
tion of new reimbursement policy from February 1, 2007. The intention of the new
policy was to reduce costs by shifting patients from esomeprazole to lansoprazole, 
omeprazole or pantoprazole. New patients should not start on esomeprazole and
ongoing esomeprazole patients should shift to a different PPI. Esomeprazole could 
be used upfront in severe cases or after having tried a different PPI ﬁ rst. METHODS:
The Norwegian Prescription Database (NorPD) contains data on all prescriptions
dispensed making it possible to follow each individual over time. All PPI prescriptions
dispensed from January 1, 2004 to January 31, 2008 were analysed. RESULTS:
For patients using esomeprazole before February 1, 2007 and having a new PPI pre-
scription dispensed the year after (n  79781), 64% continued on esomeprazole and
36% changed to a different PPI. In the latter group 57%, 20% and 23% shifted to 
pantoprazole, lansoprazole or omeprazole, respectively. 27%, 23% and 21% of those
who shifted from esomeprazole to pantoprazole, lansoprazole or omeprazole, respec-
tively, shifted back to esomeprazole again. The overall ﬁ gure was 25%. For patients
starting on PPI treatment during the year after February 1, 2007 (n  32479), 42% 
started with pantoprazole, 16% with omeprazole, 19% with lansoprazole and 23% 
with esomeprazole. Seven percent in the group of new PPI users shifted to a second
PPI. There was a profound drop in new prescriptions dispensed for esomeprazole from
57% during the last quarter before the introduction, to 26%, 24%, 22% and 20% 
during the four quarters after introduction. CONCLUSIONS: The new reimbursement 
policy for PPIs has led to signiﬁ cant changes in the pattern of prescription dispensed.
The policy was easier to implement for new patients starting on PPI treatment com-
pared to a compulsory shift for patients on ongoing esomeprazole treatment.
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OBJECTIVES: Minimizing the risk of upper gastrointestinal (GI) adverse events (AEs), 
which may compromise patient compliance with low-dose acetylsalicylic acid (LDASA) 
therapy, is an important part of cardiovascular (CV) risk management. Using data 
from the AstraZeneca ARIADNE database we assessed the risk of upper GI AEs
(including peptic ulcer disease, esophagitis and dyspepsia) and the beneﬁ ts of acid-
suppressive therapy with proton pump inhibitors (PPIs) in patients taking LDASA for 
CV risk management. METHODS: The ARIADNE database was created by Astra 
(now AstraZeneca) to store safety-related clinical study data. For this analysis, data 
on elderly patients with mild hypertension were extracted. During the follow-up
period (mean 3.7y), patients received antihypertensive therapy (hydrochlorothiazide,
plus an angiotensin II receptor antagonist or placebo) and other treatments required 
for their individual care. Among patients without a history of upper GI AEs (n 
4539), Cox proportional hazard models were used to estimate the relative risk (RR;
adjusted for age, sex, and body mass index) of upper GI AEs associated with con-
comitant use of LDASA and in relation to when PPI therapy was commenced. 
RESULTS: Overall, 1191 patients (26.2%) received LDASA during the study (with or
without concomitant acid-suppressive therapy). There was a trend towards an
increased risk of upper GI AEs in current LDASA users (RR, 1.27; 95% conﬁ dence 
interval [CI]: 0.95, 1.71). Within the subgroup using LDASA and PPIs (n  138,
11.6%) the RR of upper GI AEs was 5.41 (95% CI: 3.43, 8.53) when LDASA therapy 
was initiated before the start of PPI therapy. Adding LDASA to an existing PPI treat-
ment protected against an increased risk of GI AEs. CONCLUSIONS: These data
suggest that the risk of upper GI AEs is high in elderly patients receiving LDASA for 
CV risk management, and that PPIs confer a protective effect against upper GI AEs
in these at-risk individuals.
GASTROINTESTINAL DISORDERS – Cost Studies
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NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS: REMISSION RATES FOR
ADALIMUMAB VS. INFLIXIMAB IN CROHN’S DISEASE
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1Analysis Group, Inc., Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To compare NNTs for inﬂ iximab 5-mg/kg vs. adalimumab 40-mg 
every-other-week (eow) therapies, matching the 2 patient populations at baseline using 
statistical methods. METHODS: Remission rates for inﬁ ximab and placebo in
ACCENT I (Week-2 responders) and adalimumab and placebo in CHARM (Week-4
responders) were used. Because of the difference in CDAI scores at baseline between 
the 2 trials, unmatched and matched comparisons were made. Matching excluded 
CHARM patients with CDAI 400 and weighted remaining CHARM data for equal
baseline median and 25th and 75th percentile CDAI scores, as well as mean sex and 
median age characteristics, with ACCENT I patients. Remission NNTs for Weeks
30/26 and 54/56 were calculated, as well as weighted 56-week average remission rates. 
Cost per remitter was compared using indicated dosages and assuming complete
therapy adherence. Adalimumab’s indicated dosing equates to 32 doses/56 weeks. 
Inﬂ iximab’s indicated dosing equates to 9 infusions/56 weeks. 2008 wholesale acquisi-
tion costs (WAC) were $603.6/100 mg of inﬂ iximab and $692.47/40 mg of adalim-
umab. Administration cost per inﬂ iximab infusion was assumed to be $239.49. Patient
weight of 70 kg and ½-vial per infusion waste were also assumed. RESULTS: At 30 
weeks, the inﬁ liximab NNT was 5.56; at 26 weeks, the adalimumab unmatched and
matched NNTs were 4.34 and 3.86. At 54 weeks, the inﬂ iximab NNT was 6.80; at
56 weeks the adalimumab unmatched and matched NNTs were 4.12 and 3.72. 56-
week average for the inﬂ iximab NNT was 5.92, whereas adalimumab unmatched and
matched averaged NNTs were 4.83 and 4.77. Over 56 weeks, costs per patient were
$23,885 for inﬂ iximab and $22,159 for adalimumab. Average costs per additional 
remitter were $141,399, $107,028, and $105,698 for inﬂ iximab, unmatched adalim-
umab, and matched adalimumab. CONCLUSIONS: Based on matched and unmatched 
comparisons of data from CHARM and ACCENT I, adalimumab had better efﬁ cacy
and cost proﬁ les than inﬂ iximab.
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PUBLISHED COST-EFFECTIVENESS RESULTS FOR CHRONIC HEPATITIS 
B AND C – A COMPARATIVE ANALYSIS
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OBJECTIVES: Each year, cost-effectiveness studies are published in the area of Hepa-
titis B and Hepatitis C that have varying results. The current abstract aims to analyze
and compare the cost-effectiveness results for Chronic Hepatitis B and C across the 
different countries of publication in order to identify characteristics that can be used 
across analyses for future studies. METHODS: A systematic literature review of the
last ﬁ ve years, English only, was conducted using PubMed. Article titles were reviewed 
by two independent reviewers in order to create a reﬁ ned list for analysis. The inclu-
sion criterion for analysis was studies related to medications; publications related to 
vaccination or prevention programs were not included in the analysis. Data from the 
ﬁ nalized list of articles was then extracted. For comparison and analysis purposes, all 
results were converted to 2008 currency values and then to 2008 US Dollars using
the Purchasing Power Parities (PPP) rate published by OECD. Lastly, Incremental Cost 
Effectiveness Ratios (ICER) were compared for either Hepatitis B or Hepatitis C. 
RESULTS: A total of about 40 publications from different countries were included in 
the comparative analysis. The results reported (incremental cost per QALY or life year 
gained) varied from $142 (reported in a study from China) to over $100,000 in some 
cases. Applying the PPP helped in the comparison of results, but conclusions regarding 
commonalities (such as time horizon, comparators, target groups etc.) among results
across studies, countries and drugs prescribed could not be made. CONCLUSIONS:
Utilizing international cost-effectiveness analyses could facilitate the comparison 
among results generated by these studies. The use of international cost-effectiveness 
analyses could also allow information to be obtained about additional products and 
international experience; however these analyses should not serve as a gold standard
in health economics.
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COST EFFECTIVENESS ANALYSIS OF ANTI-TNF-ALPHA; DRUGS FOR
REFRACTORY ULCERATIVE COLITIS
Xie F, Blackhouse G, Assasi N, Hopkins R, Gaebel K, O’Reilly D, Tarride JE, Goeree RA
McMaster University, Hamilton, ON, Canada
OBJECTIVES: To evaluate cost-effectiveness of inﬂ iximab and adalimumab for
patients with refractory moderate-to-severe active ulcerative colitis (UC) in Canada. 
METHODS: A four-health state Markov model was constructed to compare cost-
effectiveness of three management strategies: A) usual care without anti-tumor necrosis
factor á (anti-TNF-á); B) 5 mg/kg inﬂ iximab for responders and adalimumab for 
nonresponders; and C) 5 mg/kg inﬂ iximab for responders, 10 mg/kg inﬂ iximab for 
those lost their response in the maintenance stage, and adalimumab for nonresponders 
to the initial therapy. ACT1 and ACT2 randomized clinical trials were two main
sources of clinical parameters. The primary outcome measure was the incremental 
cost-effectiveness ratio (ICER) between the strategies. Both deterministic and proba-
bilistic sensitivity analyses were performed. RESULTS: In the base case analysis, The
ICER was $381,133/QALY for the strategy B versus the strategy A and $609,390/
QALY for the strategy C versus the strategy A. The strategy C was dominated by the 
strategy B. The ICERs were sensitive to the remission rates, early surgery rate, and 
utility values. When the willingness to pay (WTP) was less than $150,000/QALY, the 
probability of the strategy A being the optimal strategy was 1.0. The probability of 
strategy B being optimal was 0.5 when the WTP increased to $400,000/QALY. The
probability of the strategy C being the optimal strategy was very low despite the wide
range of WTP values. CONCLUSIONS: Although inﬂ iximab and adalimumab dem-
onstrated clinical beneﬁ ts over standard treatment in patients with refractory UC, the 
cost-effectiveness of these treatments are not attractive due to signiﬁ cantly higher costs
in Canada.
